ReviewTherapeutic advances in gastroenterology2025
Artificial intelligence in inflammatory bowel disease: innovations in diagnosis, monitoring, and personalized care.
Review in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review).International journal of molecular medicine · 2026Review
- Machine Learning-Based Prediction of Treatment Response to Vitamin DBiomedicines · 2026Article
- Recent Advances in Artificial Intelligence for Endoscopic and Multimodal Assessment of Inflammatory Bowel Disease: A Review.International journal of general medicine · 2026Review
- Deep learning-based quantitative histopathology of endoscopic biopsies in Crohn's disease: a retrospective cross-sectional validation study.Frontiers in immunology · 2026Article
- The Role of Imaging in Inflammatory Bowel Diseases: From Diagnosis to Individualized Therapy.Diagnostics (Basel, Switzerland) · 2025Review
- Utility of Machine Learning to Characterize Gut Microbiota Dysbiosis and Its Clinical Implications in Inflammatory Bowel Disease.Journal of inflammation research · 2025Review
- The utility of artificial intelligence in visualization of pediatric gastrointestinal mucosa.Frontiers in pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is redefining the management of inflammatory bowel diseases (IBD) by enhancing diagnostic accuracy, refining disease classification, and optimizing disease monitoring. This review highlights AI's potential to transform IBD management by streamlining clinical workflows, improving diagnostic precision, and supporting personalized treatment strategies. By addressing the limitations of traditional clinical assessments including variability, subjectivity, and resource intensity, AI offers unbiased, consistent, and efficient solutions. Concluding with a forward-looking perspective, this paper emphasizes how integrating AI into clinical practice could lead to more precise, proactive, and patient-centric approaches to IBD care, ultimately enhancing clinical outcomes and quality of life for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.